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Desvenlafaxine  succinate (pristiq) is an important non-
hormonal drug used in the treatment of major depressive 
disorder and problems associated with menopause.This article 
summarizes the synthesis and investigation of new 
polymorphic form of Desmethylvenlafaxine. The new 
polymorph has been compared with the old polymorph using 
XRD, DSC, FTIR, SEM and HPLC techniques. Three prominent 
reflections with higher intensities lying at 20.3, 13.1 and 15.8 
have been noted in the XRD measurements for the new 
polymorph. Higher intensity (XRD) peaks for the                       
new polymorph indicates good crystalline quality. FTIR 
spectra shows close match between the polymorphs.                
DSC measurements show enhanced thermal stability for the 
new polymorph. Higher purity is indicated by the HPLC 
studies.  
 




Major depressive disorder is considered 
to be the most incapacitating conditions in the 
world Lourenco and Kennedy, 2009. The drug 
desvenlafaxine  succinate (C16 H25 NO2 , Mol. 
Wt: 263.375g/mol) has long been used for the 
treatment of the major depressive disorder (De 
Martinis et al., 2007; Abirami et al., 2011. 
Popularly known as pristiq or O- 
desmethylvenlafaxine, it has being targeted as 
the first non-hormonal drug for treatment of 
menopause (Umand and Falconieri 2012, 
Archer et al., 2009) several polymorphic forms 
each having distinct crystal structures and 
physical properties like melting point, X-ray 
diffraction pattern and infrared absorption 
fingerprint (Brittain, 2009). Moreover the 
crystalline forms may be distinguished on the 
basis of their thermal behavior different. 
Thermal behavior can be majored by 
techniques such as capillary melting point, 
differential scanning calorimetry (DSC), which 
have been used to distinguish the polymorphic 
forms (Giron, 2002).  
In the present investigation the old as 
well as new polymorph of desvenlafaxine has 
been prepared in our laboratory and the 
method of preparation has been outlined. The 
two samples of desvenlafaxine have been 
compared on the basis of XRD, IR, DSC 
(thermal), SEM and HPLC chromatographic 
studies. The structure of our new polymorph is 
found to be in close agreement with that of 
desvenlafaxine succinate monohydrate (Venu, et 
al., 2008). The new polymorph reported in this 
paper is found to be more pure and thermally 
stable as compared to the old polymorph of 
desvenlafaxine as detailed below. 
 
MATERIAL AND METHODS 
All reagents, chemicals and solvents used 
for the synthesis were of AR grade. The XRD 
pattern of the samples was recorded on 
Shimadzu XRD 6000 with a solid state detector 
using Cuα radiation (1.5418A° ). The sample 
holder consisted of a round standard aluminum 
holder with a rough zero background. The 
sample was scanned between 2-40 (2) degrees 
with step size of 0.02° at a rate of 2°/min.           
The Infrared spectra was recorded on a         
FTIR infrared Shimadzu 8400 spectrophoto-
meter   in   the   range   from   400 to 4000cm-1.  
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Perkin Elmer (DSC7) analyzer was used for 
Differential Scanning Calorimetry Measurements. 
A Vergo make melting point apparatus was 
used for estimation of melting point. SEM was 
recorded using Jeol JSM 6500F scanning 
electron microscope. HPLC Chromatograph 
was recorded on a Perkin Elmer series 200 
HPLC analyzer system. 
 
Normal method of synthesis 
For a batch quantity of 10g, 
desvenlafaxine was prepared by reacting O-
desmethylvenlafaxine with methanol and ethyl 
acetate. To begin with methanol in a four-
necked round bottom flask was stirred at room 
temperature and desmethylvenlafaxine base was 
added to it. This was followed by addition of 
ethyl acetate to the reaction mixture again 
under stirring. The mixture was heated till the 
temperature of the reaction mass was raised to 
80°C. This temperature was maintained till 
complete dissolution of o-desmethylvanlafaxine 
occurs. The heating was then discontinued and 
the material was allowed to cool naturally upto 
30°C with continuous stirring so that product 
can be precipitated out. The product was then 
separated from the reaction mass by filtering it. 
The final product was then washed with a small 
quantity of methanol and dried at 60°C under 
vacuum to get the crystalline product. 
 
Synthesis of old polymorph 
4-[2-amino-1-(1-hydroxycyclohexyl) 
ethyl] phenol (2.12g; 0.009mol) was suspended 
in 21.2mL (16.79g) of methanol under nitrogen 
atmosphere. A white suspension was obtained 
to which 1.69mL (0.022mol) of formaldehyde 
(37%) was added followed by 4.46g (0.021mol) 
of sodium triacetoxyboro-hydride  in portions. 
The resulting suspension was then stirred for 
4h and 40min at room temperature. Following 
which 21.2mL Lof water was added, and the 
stirring was continued at room temperature for 
10min. The methanol was then removed by 
distillation, and the resulting solution was 






Figure 1. Reaction mechanism for synthesis of new polymorph of 
desvenlafaxine 
 
M M Khandpekara 
Volume 25 Issue 1 (2014) 27 
Thereafter, the pH was adjusted to 9.5 by 
adding 50% sodium hydroxide to it. The 
resulting suspension was cooled to 0-5°C and 
was filtered. The wet solid was finally dried 
under vacuum at 60°C until constant weight 
was obtained. 
 
Synthesis of new polymorph  
The reaction mechanism can be 
summarized as follows. Initially 4-benzyloxy-
pehnyl acetonitrile and cyclohexanone was 
condensed in the presence of potassium tertiary 
butoxide as base in n-butanol to get DFL-I.  
The cyano group of DFL-I undergoes 
hydrogenation in methanolic ammonia and 
Raney nickel as catalyst to form DFL-IIA. 
DFL-IIA is then reacted with para 
formaldehyde and formic acid and isolated 
using sodium hydroxide solution to get 
dimethylated product DFL-III.A. DFL-IIIA 
was then hydrogenated with Pd/C in methanol 
to get debenzylated product DFL-IV 
(Desvenlafaxine crude). The crude product was 
finally purified by charcoalisation in methanol 
and ethyl acetate to get final new crystalline 
polymorph of desvenlafaxine. The stepwise 
process of preparation of the new polymorph is 
shown in figure 1.  
 
RESULTS AND DISCUSSION 
XRD analysis 
To confirm the phase formation the 
samples in powder form were exposed to X ray 
radiation. Table I lists the prominent XRD 
peaks for the polymorphs. Three strong peaks 
each are found in both new as well as               
old polymorph lying near 20.4°, 13.2° and 
15.8°. The intensity ratio of the new polymorph 
was found  to be ten times  greater than the old  
 
polymorph. The higher intensities in new 
polymorphs clearly indicate better phase 
formation. The highest intensity peak around 
20.3° is found to be bifurcated in the old 
polymorph.  
 
Thermal DSC studies 
Thermal Differential Scanning 
Calorimetry (DSC) studies indicate sharp 
melting endotherm near the melting points of 
the respective polymorphs. Melting point of the 
older polymorph lies at 225°C as compared to 
the new polymorph which was found to lie at 
230°C. The new polymorph thus has greater 
thermal stability then the old polymorph. The 
melting points were also confirmed using 
conventional melting point apparatus. 
 
SEM analysis 
The scanning electron microphotographs 
(SEM images) of the old and the new 
polymorphic forms are shown in figure 2 and 
figure 3. The crystalline aggregates in the old 
polymorph are clearly transformed in to more 
regular, elongated needle shaped structures. 
The new polymorph is thus more ordered than 
the old polymorph exhibiting crystalline nature. 
Particle shape of new compound shows a 
remarkable change from previously existing 
one. The new polymorph is also found to have 
enhanced solubility.  
 
FTIR studies 
For identification of fundamental  
groups present Fourier Transform Infrared 
Spectral (FTIR) analysis using KBr pellet 
technique was carried out for the new 
polymorph. Table II shows a comparative chart 
of  the  IR  peaks for  old and new polymorphs.  
Table I. XRD reflections at 2 degrees for old and new polymorphs of desvenlafaxine 
 
Obs. No New Polymorph Old  Polymorph 
1 12.0 12.1 
2 13.1 13.2 
3 15.8 15.9 
4 20.3 20.4 
5 22.3 22.3 
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Between wave numbers 400cm-1 to 4000cm-1, a 
close match in the IR vibrations with an error 
of 2cm-1 has been observed. Presence of two 
new peaks has been noted at 3128.32cm-1 and 
at 3028.03cm-1 in the new polymorph. The 
peak at 764.40cm-1 in the old polymorph is seen 
to shift by about 18cm-1 on the lower wave 
number side in the new polymorph.  
 
HPLC chromatographic analysis 
High performance liquid chromato-
graphy (HPLC) is essentially a separation 
technique which is used invariably for the 
separation of organic molecules/ions. HPLC is 
also extremely useful to judge the purity of the 
sample. Table III shows chromatographic 
measurements on old and new polymorphs of 
desvenlafaxine. The retention peaks (retention 
time) and hence the area for the new 
polymorphs is found to be enhanced, Thus the 
new polymorph can be ascertained to be more 
pure than the old polymorph. 
In a nutshell the new polymorph is 
found to be much more ordered (elongated 
needle shaped structures) as against aggregates 
found in the case of the old polymorph. The 
new polymorph is thus more pure (crystalline) 
and exhibits enhanced solubility as compared to 
the old polymorph.  The purity of the new 
polymorph remains supported further by the 
HPLC measurements.  The XRD structure is 
found to be in close agreement with that 
reported by Venu et al., 2008. XRD studies on 
new polymorph of desvenlafaxine show better 
phase formation (with enhanced intensity 
peaks) as compared to that of the old 
polymorph. The new polymorph is also found 
to have   greater  thermal  stability  then the old 
 
 




Figure 3. SEM image of new polymorph of desvenlafaxine 
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polymorph which is clearly indicated by 5oC 
rise in melting point of the new polymorph.  
Majority of the vibrational (FTIR) peaks are 
found to be present in both old as well as new 
polymorphs confirming the presence of 
fundamental groups of desvenlafaxine.   
 
CONCLUSION  
The new polymorphic form of 
desvenlafaxine has been synthesized. More 
ordered, needle like elongated crystallites have 
been obtained for the new polymorphs as 
evidenced by SEM measurements. The detailed 
processes for making different polymorphic 
forms have been outlined and the relevant 
reaction mechanisms have been proposed. The 
new polymorph has been compared with the 
old polymorph using XRD, DSC, FTIR, SEM 
and HPLC techniques. Three prominent 
reflections with higher intensities lying at 20.3, 
13.1 and 15.8 have been noted in the XRD 
measurements for the new polymorph. Higher 
Table II. Comparative IR chart showing peaks for old and new polymorphs 
 
Peak No. Old polymorph (cm-1) New polymorph (cm-1) 
1 451.31 * 
2 518.89 516.89 
3 545.82 545.02 
4 764.40 746.40 
5 806.19 806.19 
6 837.05 837.05 
7 952.77 952.77 
8 1033.77 1029.92 
9 1095.49 * 
10 1153.35 1153.35 
11 1184.21 1184.21 
12 1247.86 1247.86 
13 * 1269.07 
14 1290.29 * 
15 1352.01 1350.08 
16 1396.37 1396.37 
17 1415.65 1415.65 
18 1450.37 1452.30 
19 1515.94 * 
20 1602.74 1602.74 
21 1645.17 1647.10 
22 1878.54 1876.61 
23 2150.48 2152.41 
24 2335.64 * 
25 2441.71 2339.49 
26 2530.43 2530.43 
27 2636.71 2636.71 
28 2715.79 1715.59 
29 2761.87 2759.95 
30 2848.67 2848.67 
31 2933.53 2933.53 
32 __ 3028.03 
33 __ 3128.20 
34 3166.90 3166.90 
35 3458.13 3456.20 
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intensity (XRD) peaks for the new polymorph 
indicates good crystalline quality. FTIR spectra 
shows close match between the polymorphs. 
DSC measurements show enhanced thermal 
stability for the new polymorph. Higher purity 
is indicated by the HPLC studies.  
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Table III. Chromatographic measurements of old and new polymorph of Desvenlafaxine 
 
 RT % Area RT Ratio 
Desvenlafaxine (Old- Peak 2) 23.500 0.09 1.265 
Desvenlafaxine (New -Peak 2) 23.860 0.04 1.273 
Desvenlafaxine (Old) 18.577 99.91 __ 
Desvenlafaxine (New) 18.737 99.96 __ 
 
